Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Monopar Therapeutics Inc ( (MNPR) ) has shared an update.
Monopar Therapeutics Inc. announced promising early results from its MNPR-101-Zr Phase 1 clinical trial, showcasing the compound’s ability to specifically target tumors in cancer patients. The trial’s positive outcomes, based on PET imaging, validate the targeted approach of MNPR-101-Zr, a humanized monoclonal antibody, against cancers with high expression of the urokinase plasminogen activator receptor, such as triple-negative breast, colorectal, and pancreatic cancers. These findings pave the way for future therapeutic developments, with additional data set to be presented at a prestigious medical congress.
See more data about MNPR stock on TipRanks’ Stock Analysis page.
